https://proteasomesignal.com/i....ndex.php/food-insecu
But, EGCG has its own shortages, e.g., fairly unstable, reduced lipid solubility, bad bioavailability, and quick timeframe of activity. GOAL OF THE STUDY to conquer the shortages of EGCG for antiangiogenic antitumor usage, our research developed a novel EGCG derivate, Y6(5,3',4',3″,4″,5″-6-0-ethyl-EGCG). The underlying method was also elucidated. INFORMATION AND METHODS we evaluated the effects of EGCG, Y6 on HCC and angiogenesis in vivo plus in vitro